Jupiter Topco LLC Takes Position in Agios Pharmaceuticals, Inc. $AGIO

Jupiter Topco LLC acquired a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 23,797 shares of the biopharmaceutical company’s stock, valued at approximately $883,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Sei Investments Co. increased its holdings in Agios Pharmaceuticals by 342.8% during the first quarter. Sei Investments Co. now owns 63,550 shares of the biopharmaceutical company’s stock valued at $2,150,000 after buying an additional 49,198 shares during the last quarter. SCS Capital Management LLC purchased a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth $22,743,000. State of New Jersey Common Pension Fund D bought a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at $1,291,000. GW&K Investment Management LLC grew its position in shares of Agios Pharmaceuticals by 41.5% during the 4th quarter. GW&K Investment Management LLC now owns 1,207,301 shares of the biopharmaceutical company’s stock valued at $32,863,000 after acquiring an additional 354,359 shares during the period. Finally, Seven Fleet Capital Management LP purchased a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth $864,000.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on AGIO. JPMorgan Chase & Co. raised their target price on Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. HC Wainwright boosted their price target on Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Truist Financial decreased their price objective on Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. TD Cowen raised Agios Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 24th. Finally, Royal Bank Of Canada boosted their price objective on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a research note on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Agios Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $41.25.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 30,000 shares of the stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total transaction of $914,400.00. Following the completion of the sale, the insider directly owned 54,645 shares of the company’s stock, valued at $1,665,579.60. This trade represents a 35.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by insiders.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock opened at $33.10 on Friday. Agios Pharmaceuticals, Inc. has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The company has a market capitalization of $1.98 billion, a P/E ratio of -4.72 and a beta of 0.60. The company has a fifty day moving average of $35.64 and a 200 day moving average of $31.84.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The business had revenue of $44.75 million during the quarter, compared to analysts’ expectations of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. Analysts forecast that Agios Pharmaceuticals, Inc. will post -5.82 EPS for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.